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http://dx.doi.org/10.1016/j.pedneo.2Background: Kawasaki disease (KD) is a type of febrile self-limiting systemic vasculitis, which
affects the coronary arteries (CA) and may cause cardiac ischemia during childhood and adult
life. Intravenous immunoglobulin (IVIG) has become the standard therapy for KD. However, it is
still uncertain if CA outcome is associated with the timing of IVIG administration with refer-
ence to fever onset.
Methods: The present study was designed to identify the risk for development and delay in res-
olution of CA abnormalities in association with IVIG administration within or after 10 days of KD
onset. A retrospective analysis of clinical signs, laboratory data, and prospectively collected
echocardiography (ECHO) results of 106 children hospitalized with KD was utilized.
Results: IVIG was administered to 86 (81.1%) patients within 10 days, and 20 (18.9%) patients
received the first dose of IVIG after 10 days of illness. Among 23 (21.6%) patients who were diag-
nosed with CA lesions, 18 had a CA abnormality at initial ECHO, whereas they appeared after
IVIG therapy in five patients. The risk for CA lesions on initial ECHO was higher among the pa-
tients who were admitted after 10 days of disease onset [odds ratio (OR)Z 5.3, 95% confidence
interval (CI) Z 1.7e15.9] but comparable with the post-IVIG treatment group (OR Z 3.1, 95%
CIZ 0.48e19.8). The age<1 year and erythrocyte sedimentation rate (ESR)> 40 mm/hour were
associated with non-resolution of CA lesions within 9 weeks of KD onset. Overall, 95.6% of chil-
dren had resolution of CA abnormalities within 6 months of onset of KD symptoms.Children’s Hospital, Jersey Shore University Medical Center, Division of Pediatric Infectious Diseases,
54, USA.
ers.edu (A.K. Bal).
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388 A.K. Bal et alConclusion: The results of this study suggest that although IVIG treatment within 10 days is
important to minimize development of cardiac pathology, neither occurrence of CA lesions in
IVIG-treated children nor the time frame for resolution of established CA abnormalities was asso-
ciated with the timing of IVIG administration. Age<1 year and high ESR (>40 mm/hour) predict a
delay in resolution of CA lesions among children with KD.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Kawasaki disease (KD) is an acute, febrile, self-limiting
vasculitis of unknown etiology which leads to the formation
of ectasia, dilatation, or aneurysm of the coronary arteries
(CA) in approximately 25% of untreated children.1e4 This
disease has become the leading cause of acquired heart
disease among children in the United States and other
developed countries.1 Consequential myocardial ischemia
and/or infarction have been recorded not only shortly after
KD, but also during later adult life in affected children.5e7
The consensus statement of the American Heart Association
(AHA), along with other organizations including the Amer-
ican Academy of Pediatrics, identified post-KD children as
being at risk for atherosclerotic coronary arterial diseases
depending on the status of the CA lesions.8 Treatment with
a high dose of intravenous immunoglobulin (IVIG) within 10
days from the onset of illness substantially reduced the risk
for development of CA pathology as compared with un-
treated patients.2e4,9 Administration of IVIG after the 10th
day of illness due to delayed diagnosis in 25% of the KD
cases increased the risk for the development of CA
lesions.10e12 The United States Multicenter Kawasaki Dis-
ease Study Group concluded that all patients who are
diagnosed with KD should be treated with IVIG, because the
scoring of clinical and laboratory data is imperfect in the
prediction of CA lesions in children with KD.13 The AHA
recommends administration of IVIG to KD patients within 10
days and also after Day 10 of the illness, if the patients
show unexplained persistent fever or develop CA lesions,
although the potential effect of delayed IVIG treatment
remains uncertain.14 Therefore, the effect of delayed IVIG
treatment (>10 days) on CA pathology is still a subject for
discussion. Muta et al15 reported no difference in the
probability of occurrence of CA abnormalities after IVIG
treatment for children receiving IVIG within 8 days or after
10 days of the onset of fever. No study has investigated the
risk for the development of CA lesions in association with
the timing of IVIG administration within and after Day 10 of
disease onset. Moreover, no study has analyzed the asso-
ciation between appropriate or delayed IVIG treatment and
resolution of established CA lesions. In one brief report,
IVIG treatment of KD patients was associated with a
decreased risk for incomplete resolution of CA lesions as
compared with patients receiving only aspirin.16
The present study was designed to delineate the risk for
the occurrence and resolution of CA pathology in associa-
tion with the timing of IVIG treatment (10 days and >10
days of KD onset) independently from age and level of
acute phase of inflammation. The results of this study will
advance our understanding of the role of the timing of IVIGtreatment, patient age, clinical signs, and laboratory in-
flammatory markers in the occurrence and resolution of CA
lesions in children with KD.
2. Methods
The present study was approved by the Jersey Shore Uni-
versity Medical Center (JSUMC) Institutional Review Board.
A cohort of children (0e18 years of age) with KD who were
hospitalized at the JSUMC from January 1999 to December
2011 and followed in a single Pediatric Cardiology Clinic
was identified as participants for this study. Their de-
mographic, clinical, and laboratory data during the hos-
pitalization were extracted from the medical records. The
KD was classified in accordance with the existing guide-
lines.14,17 Diagnosis of KD was established if the child had
fever for at least 5 days along with: (1) four major symp-
toms, or (2) less than four major symptoms with CA ab-
normality based on echocardiography (ECHO) testing at
the time of hospitalization. The identified laboratory data
on admission were categorized as abnormal if the eryth-
rocyte sedimentation rate (ESR) was >40 mm/hour, C-
reactive protein (CRP) level was >3 mg/dL, platelet count
was 500,000/mL, and white blood cell count (WBC) was
>15,000/mL.17,18 The results of the initial and consecutive
echocardiograms at 3e4 weeks, 4e6 weeks, 6e9 weeks,
and 6e12 months from onset of KD were collected from
the medical records in the hospital and the Pediatric
Cardiology Clinic. An ECHO was performed: (1) for all
children at the time of hospitalization and at 3e4 weeks;
(2) for 94.4% of patients at 4e6 weeks; (3) for 45.3% of
patients at 6e9 weeks; and (4) for all children with
established CA lesions at 9e12 months of KD onset. All
initial echocardiograms were obtained by the Acuson
Sequoia C512 (manufactured by Siemens Medical Solu-
tions, Mountain View, CA 19043 USA) using the 10V4 probe.
Follow-up echocardiograms were performed using the S8
probe of the HP Sonos 5500 machine (manufactured by HP,
Philips, Bothel, WA 98041 USA). CA lesions including dila-
tion, ectasia, or aneurysms were classified as CA pathology
in accordance with the AHA guidelines.14 We collected
evidence of non-therapeutic responses characterized by
persistence or recrudescence of fever lasting >36 hours
after completion of the IVIG infusion.14
All children with confirmed KD received 2 g/kg of IVIG
(Carimune, Flebogamma or Gamunex) over 12 hours. Aspirin
(100 mg/kg) was given orally until the patients became
afebrile for 96 hours followed by 4e6 mg per kg of body
weight until 6 weeks after onset of illness. Children with
abnormal ECHO continuously received aspirin (4e6 mg/kg)
until resolution of coronary abnormality on echocardiogram.
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The collected data were stratified with respect to the
time of IVIG treatment, i.e., within 10 days or after 10
days of disease onset. The Chi-square test was used for
the comparison of categorical and ANOVA for continuous
data between the study groups. Data are presented as a
percentage and mean  standard deviation. Three sets
of multivariate regression analysis were performed
to identify the factors that may have an association
with: (1) the development of CA lesions before IVIG
treatment; (2) development of new cases with CA le-
sions after IVIG treatment; and (3) resolution of estab-
lished CA lesions within 9 weeks of fever onset. We
performed multicollinearity analysis that included cor-
relation analysis (Pearson’s r > 0.70) among the pre-
dictors in the models. In addition, the tolerance and
variance inflation factor (VIF) was analyzed to identify
the collinearity with cut-off for tolerance >0.1 and VIF
<5 that indicated lack of multicollinearity among the
predictor variables in the tested model. Statistical sig-
nificance was identified with a p value < 0.05. Statisti-
cal analysis was performed using Statistica 10.0
(StatSoft, Tulsa, OK, USA).3. Results
One hundred and six children with KD were included in this
study. All hospitalized patients were initially treated with
IVIG (2 g/kg) in a time frame ranging from 5 to 20 days of
fever onset, and three patients who did not respond to the
first injection of IVIG received a second dose. No other
treatment except aspirin was provided for the hospitalizedTable 1 Demographic and clinical characteristics of children w
immunoglobulin (IVIG) treatment.
Characteristics Tim
10 d (n Z 86)
Age (y) 3.5  2.6
Age <1 y 19.8
Sex (male) 65.1
Race/ethnicity
White 91.8
Black 3.5
Hispanic
Asian 4.7
Conjunctival injection 93.0
Oral mucosal changes 93.0
Cervical lymphadenopathy 79.1
Polymorphous exanthema 82.6
Swelling of the extremities 53.5
Peeling 19.8
Atypical KD 7.0
WBC > 15  106/mm3 31.4
ESR > 40 mm/h 80.2
Platelets > 500,000/ml 23.5
CRP > 3 mg/dL 63.9
Data are presented as (%) or mean  SD.patients. Eighty-six patients (81.1%) received the first dose
of IVIG within 10 days (7.2  1.7 days) and 20 children
(18.9%) after 10 days (13.7  2.9 days) of the disease onset.
Among three patients who received two doses of IVIG, two
had been treated with the first dose after 10 days of disease
onset. As shown in Table 1, the demographic and clinical
characteristics of the patients stratified by the time of IVIG
treatment (within 10 days vs. >10 days) were comparable,
except for the higher prevalence of cervical lymphade-
nopathy and swelling of the extremities in children who
were admitted within 10 days and peeling that was recor-
ded at a higher frequency in children who were admitted
after 10 days of disease onset. Overall, among the 106
patients included in the study, 23 (21.7%) were diagnosed
with CA lesions. Aneurysm was diagnosed in 60.9% of 23
children with CA lesions. CA abnormalities were diagnosed
at initial ECHO in 18 patients (78.3%). Following IVIG ther-
apy, five children developed a CA abnormality on follow-up
ECHO at 3e4 weeks from the onset of symptoms, which
accounted for 5.7% out of 88 of unaffected patients. The
distribution of the types of CA lesions with respect both to
time of IVIG administration (within vs. after 10 days) and
recording of CA pathology (at initial ECHO and at 3e4
weeks) is presented in Table 2. As shown in Table 2, an-
eurysms were recorded in 70% of 10 children diagnosed with
CA lesions and treated after 10 days and in 53.9% of 13
children with CA lesions who received IVIG within 10 days
(p Z 0.23).
The frequency of CA lesions on initial ECHO was higher in
children hospitalized after 10 days of disease onset as
compared to those who were admitted before 10 days
(Figure 1). As shown in Figure 1, the risk for development of
CA pathologies at the post-IVIG treatment stage was
slightly, but not significantly, higher in children treatedith Kawasaki disease (KD) based on the time of intravenous
e of IVIG treatment p
>10 d (n Z 20)
2.9  1.7 0.361
25.0 0.603
55.0 0.398
85.0 0.079
10.0
5.0
e
80.0 0.072
80.0 0.073
55.0 0.026
85.0 0.793
20.0 0.006
45.0 0.018
15 0.246
50.0 0.115
90.0 0.304
35.0 0.290
60.0 0.304
Table 2 Distribution of coronary artery (CA) lesions by type with respect to time of diagnosis and intravenous immunoglobulin
(IVIG) administration.
CA lesions IVIG  10 d IVIG > 10 d
Initial ECHO ECHO at 3e4 wk Initial ECHO ECHO at 3e4 wk
Aneurysm 40% (4/10) 100% (3/3) 62.5% (5/8) 100% (2/2)
Ectasia 60% (6/10) d 37.5% (3/8) d
ECHO Z echocardiography.
390 A.K. Bal et alafter 10 days as compared with those who received IVIG
after 10 days of KD onset.
Overall, resolution of CA lesions within 9 weeks was
recorded in 65.2% of the 23 children with CA pathological
findings. Among the children who received IVIG after 10
days and who were diagnosed with CA lesions, 50% showed
resolution as compared to 76.9% among children who
received IVIG within 10 days of fever onset (pZ 0.178). The
follow-up ECHO showed resolution of CA lesions in 22/23
(95.65%) children within 6 months of the disease onset.
Persistence of CA pathology during the 12 months of follow
up was recorded in one child who received IVIG after 10
days of disease onset and who was diagnosed with a giant
CA aneurysm at 3e4 weeks of disease onset.
Table 3 summarizes the multivariate regression analysis,
which was designed to identify factors that may influence
the development of CA lesions before treatment (Model 1),
after treatment (Model 2), and resolution of CA lesions
within 9 weeks of disease onset (Model 3). We found that
children with established CA lesions were likely to have a
prolonged duration (>10 days) of disease before IVIG
treatment (Model 1). Patients with a normal initial ECHO
who developed CA lesions after the IVIG treatment tended
to be <1 year of age. Time before treatment and pathologic
laboratory findings did not affect the occurrence of post-
treatment CA lesions (Model 2). Model 3 included vari-
ables that may have an association with delayed resolution
of CA lesions in affected children. The results showed that
the time of IVIG treatment was not significantly associated
with the resolution of CA lesions. Children <1 year of age11.6%
3.4%
40%
10%
0
10
20
30
40
50
60
70
80
90
100
After IVIG (at 3-4 wk)Before IVIG (at admission)
 ≤ 10 d (n = 86)  > 10 d (n = 20)
OR 5.3, 95% CI 1.7-15.9  
OR 3.1, 95% CI 0.48-19.8 
Figure 1 Frequency of diagnosed coronary artery (CA) le-
sions in children with Kawasaki disease (KD) with respect to the
time of intravenous immunoglobulin (IVIG) administration.
CI Z confidence interval; OR Z odds ratio.and with an ESR >40 were associated with non-resolution of
CA lesions within 9 weeks of KD onset. We also included in
Model 3 the type of CA lesions, because we found that
aneurysms were more likely to occur among infants than
older children (81.8% vs. 41.7%, p< 0.05). The type of CA
lesion was not significantly associated with a risk for
delayed resolution of CA pathological findings
(b Z e0.274  0.245, p > 0.05).
We found no multicollinearity between the model vari-
ables. Among all pairs, a significant correlation was found
only between ESR and age (r Z e0.267, p< 0.01) sug-
gesting a lack of multicollinearity. Moreover, the tolerance
and VIF also indicated a lack of multicollinearity, because
tolerance was > 0.1 (0.867, 0.898, 0.897, 0.924, and 0.962)
and VIF was <5 (1.15, 1.11, 1.12, 1.08, and 1.03) for age,
WBC, ESR, CRP, and treatment groups (<10 days vs. 10
days), respectively.4. Discussion
In this study we estimated the risk level for occurrence or
incomplete resolution of CA abnormalities in children with KD
with respect to the time of IVIG administration within and
after 10 days of fever onset. As in previous reports,10,12 we
recordedahigher risk fordevelopmentofCA lesions if IVIGwas
administrated after 10 days of disease onset. For instance,
childrenwith CA lesions diagnosed at initial ECHO had a 23.7%
higher likelihood of being treated after Day 10 than thosewho
received IVIG within 10 days of onset of fever, independently
from the age and level of inflammatory markers. A significant
beneficial effect of IVIGadministrationbefore 10days of fever
(as compared with patients not treated with IVIG within 10
days) was identified in randomized clinical trials.19 Because
IVIG is more likely to be able to interrupt vascular inflamma-
tion in the acute stage of illness, 10 days of fever was identi-
fied as an appropriate cut-off point for IVIG administration.
Although IVIG treatment within 10 days was recognized as an
evidence-based standard,14 the best time for IVIG treatment
with respect to the fever onset is still debatable. Observa-
tional studies have shown that patients treated by Day 7 of
illness may develop aneurysms significantly less frequently as
compared to those who are treated between Days 8 and 10 of
illness.20,21 Additionally, genotype polymorphisms may pre-
dict IVIG treatment response and susceptibility to KD.22 None
of the IVIG responder children required re-administration of
IVIGtodecrease the risk fordevelopmentofCApathology.23,24
Children with KD are still at risk for coronary abnormalities
after IVIG administration.15,25 A risk of 8% has been reported
for CA lesions irrespective of the administration of IVIGwithin
8 or after 10 days of fever onset.15 In our study, the overall risk
Table 3 Factors that were associated with: (1) coronary artery (CA) lesions diagnosed at the initial echocardiography (ECHO)
(Model 1); (2) CA lesions diagnosed after intravenous immunoglobulin (IVIG) treatment (Model 2); and (3) resolution of CA lesions
within 9 weeks of Kawasaki disease (KD) onset (Model 3).
Variables B  standard error
Model 1 Model 2 Model 3
IVIG > 10 d (n Z 20) 0.237  0.095* 0.111  0.068 0.129  0.211
Age < 1 y old (n Z 22) 0.166  0.107 0.321  0.072 ** 0.696  0.230*
WBC > 15  106/mm3 (n Z 37) 0.121  0.085 0.063  0.056 0.454  0.217
ESR > 40 mm/h (n Z 87) 0.049  0.108 0.041  0.066 0.711  0.261*
CRP > 3 mg/dL (n Z 58) 0.021  0.084 0.072  0.053 0.189  0.263
Dummy variables of: (1) IVIG treatment: equals 1 if treatment conducted after 10 days and 0 if within 10 days; (2) CA lesions: equals 1 if
CA lesions were diagnosed and 0 if not; (3) resolution of CA: equals 1 if CA lesions resolved within 9 weeks and 0 if not; (4) age: equals 1 if
age less than or equal to 12 months and 0 if not; (5) WBC: equals 1 if WBC > 15  106/mm3 and 0 if not; (6) ESR: equals 1 if ESR > 40 mm/
h and 0 if not; (7) CRP: equals 1 if CRP > 3 mg/dL and 0 if not.
*p < 0.02. **p < 0.0001.
CRP Z C-reactive protein; ESR Z erythrocyte sedimentation rate; WBC Z white blood cell count.
IVIG therapy and coronary artery abnormality risk in children with Kawasaki disease 391for development of CA lesions after IVIG treatment in the
unaffectedpatients at the initial ECHOwas around6%,withno
significant difference among patients who received IVIG
within 10 days or after Day 10. Infants diagnosedwith KDwere
significantly more likely (by 32.1%) to develop CA lesions after
IVIG treatment as compared with older children. The younger
age-associated risk for KD susceptibility and development of
CA abnormalities has been previously reported.26e29 We also
showed that the probability for incomplete resolution of CA
lesions within 9 weeks was approximately 70% higher among
infants and in children with KDwho had an ESR> 40mm/hour
at the time of admission.
We have to acknowledge several limitations of the pre-
sent report. First, the study results could have been limited
by its retrospective design. However, information bias was
possibly covered by reliable measurements of well-
documented exposure (time of IVIG administration) and
outcome (occurrence and resolution of CA lesions) variables.
ECHO was performed on each individual in the assigned time
frame during the follow up at a single Pediatric Cardiac
Clinic. Moreover, ECHO data were blinded to the time of IVIG
treatment. Additionally, the population-based design of the
study reduced the impact of selection bias because all
eligible cases diagnosed with KD who were hospitalized and
followed in the Pediatric Cardiology Clinic during the 12-year
period were included. We also used statistical adjustment
for the ‘measurable with high accuracy’ known confounders
(age and laboratory-reported inflammatory markers) to
identify the independent effect of time of IVIG treatment
within or after Day 10 of fever onset, although one of the
important laboratory parameters, albumin,was not included
because it was not consistently tested in all participants.
Because of ethical considerations, no experimental design is
available to identify the difference in CA outcomes between
delayed (after 10 days) and timely IVIG treatment in children
with KD. Secondly, due to the inconsistency in the frequency
of laboratory testing, only initial laboratory measurements
were analyzed in the present study. However, the study
showed that for most of the KD cases, only the baseline
laboratory measurements appeared to be good predictors of
CA involvement during early follow-up.30 Thirdly, the data
were not analyzed in respect to the CA abnormalitiesbecause a larger study is needed to achieve the power to
detect the effect of size of type of CA lesions on the time of
resolution of CA pathologies.
We conclude that administration of IVIG within 10 days
of onset of illness is important to minimize the risk for
development of cardiac pathology, but that this does not
significantly impact either the occurrence of CA lesions in
IVIG-treated children or time of CA lesion resolution. Infant
age group and high ESR should be considered for prediction
of delayed resolution of CA lesions in children with KD.Conflicts of interest
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